Quantcast
Skip to content

Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit neb.

Retroviruses – Friends or Foes?

Content brought to you by New England Biolabs

The word ‘retrovirus’ evokes images of HIV, the AIDS pandemic and a desperate worldwide effort to defeat this mighty adversary. But on the flip side, scientific research has managed to tame the virus and use it as a tool for advancement.

Retroviruses are commonly used to introduce genes into mammalian cells to express or knockdown genes of interest. In addition, retroviruses are being developed for use in gene therapy. Though the use of retroviruses raises safety issues, new molecular and genetic techniques of vector design circumvent concerns and make them widely available for safe use in the lab and as potential gene therapy agents.

Pros and cons of retroviral vectors

Compared to other modes of gene delivery such as classical chemical based transfection, electroporation, and microinjection, retroviruses have the following characteristics:

Pros:

  • The DNA integrates into the host cell genome and replicates stably with genomic DNA instead of remaining in a plasmid form in the cytoplasm
  • They have low immunogenicity
  • Lentiviruses (as opposed to standard modified retroviruses like MMLV) can infect both dividing and quiescent cells

Cons:

  • Smaller insert carrying capacity
  • Risk of insertional mutagenesis – accidental insertion of retroviral DNA into an unintended site causing disruption of host gene function
  • Lower titers (than other viral vectors)
  • Low replication efficiency in self-inactivating (SIN) vectors

Special concerns for using retroviral vectors

In 1990, Nobel laureate Howard Temin, who co-discovered the reverse transcriptase enzyme, detailed the risks and safety considerations associated with retroviral vectors, but stated that “safety considerations should not hold up further human trials of retrovirus vectors”.

However, immediately after in 1992, in a pre-clinical trial in rhesus monkeys, a retrovirally-transduced bone marrow transplant led to development of fatal lymphomas in 3 out of 10 recipients, the cause being formation of replication-competent viruses. Thus, the theoretical chance of formation of replication-competent virus particles that cause infections and of viral integration into the host genome causing oncogenesis and mutations cannot be ignored.

Increasing safety

This has led to intense research and development of viral vector strategies and newer technologies that make retroviral work safer. Some of these are:

Replication-deficient

Retroviral vectors used in research are made replication-deficient. Genes required for viral infection but unnecessary for packaging and transduction are deleted. Viral structural genes that are incorporated into the plasmid do not contain a ? (psi) sequence (which essentiallyhelps to incorporate the RNA into viral particles) thus making replication-deficient viruses.

Split genomes

The viral packaging genes essential for viral particle production and transduction are split into multiple plasmids to decrease the frequency of recombination events between the genes that lead to formation of replication-competent viruses. Thus, three and even four different plasmids are utilized to transfect packaging cell lines and produce viral particles.

Self-inactivation

Higher biosafety is ensured in newer systems due to genetic modifications in the transfer plasmid making it easy to integrate into the host genome but prevent activation afterwards (called a SIN or self-inactivating vector).

Tropism

Depending on the type of viral envelope proteins, three types of viruses can be made:

  1. Pantropic – can infect cells of all species
  2. Ecotropic – can infect cells of mouse and rat origin
  3. Amphotropic – can infect human, mouse and rat cells

Ecotropic viruses are the safest to use, as they cannot infect human cells. (Though consider the fact that ecotropic and amphotropic viruses are less stable than pantropic viruses).

Containment

All retroviral work is carried out in a BSL2 (or BSL3 for certain experiments like work with HIV) containment facility and is strictly governed by institutional guidelines.

Tips for keeping safe

If you are going to be working with retroviruses:

  • Get trained to work with viruses, viral particles and biological material
  • Wear the correct PPE (Personal protection equipment)
  • Be informed as to emergency response and spill procedures
  • Be extra careful with sharps and bio hazardous materials
  • Know the right protocols for waste disposal and management
  • Follow exact experimental protocols and safety procedures
  • Report accidents, spills and unusual incidents

References

1 Comment

  1. Dave on May 10, 2018 at 2:40 pm

    I don’t understand the paragraph about retroviruses being replication deficient. You say “Genes required for viral infection but unnecessary for packaging and transduction are deleted”. First, what is the difference between infection and transduction? Then you go on to say “Viral structural genes that are incorporated into the plasmid do not contain a ? (psi) sequence (which essentiallyhelps to incorporate the RNA into viral particles)”. The first sentence says that packaging is not affected, but the second sentence says that structural genes lack the Psi sequence which is required for packaging. How is replication prevented, and how does that affect the use of retrovirus as a tool for gene expression/knock-down?

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll To Top
Share via
Copy link